Phospho-PRKCQ-T538 Rabbit Polyclonal Antibody for WB, ELISA - Q04759

Core Product Specifications and Parameters

Biological Background: PRKCQ Function and Localization

• PRKCQ (Protein kinase C theta type, nPKC-theta) is a calcium-independent, phospholipid- and diacylglycerol-dependent serine/threonine-protein kinase that plays non-redundant roles in T-cell receptor (TCR) signaling.
• In TCR-CD3/CD28-co-stimulated T-cells, it is required for activation of NF-kappa-B and JUN, essential for IL2 production, and participates in NFATC1/NFATC2 transactivation. Related references: PMID:21964608
• It mediates canonical NF-kB pathway activation by phosphorylating CARD11, leading to recruitment of the BCL10-MALT1 complex and IKK activation.
• PRKCQ is critical for T-helper cell differentiation, being necessary for Th2 and Th17 cell development, and plays a minor role in Th1 response; it also provides survival signals by phosphorylating BAD and upregulating BCL-XL.
• Beyond T-cells, in platelets it regulates signal transduction downstream of ITGA2B and other receptors, playing a positive role in outside-in signaling and granule secretion.
• It may mediate inhibitory effects of free fatty acids on insulin signaling by phosphorylating IRS1, thereby blocking PI3K/AKT pathway activation.
• PRKCQ phosphorylates CCDC88A/GIV and inhibits its guanine nucleotide exchange factor activity. Related references: PMID:23509302
• It also activates LRRK1, which phosphorylates RAB proteins involved in intracellular trafficking. Related references: PMID:36040231
• Subcellular localization: Cytoplasm and cell membrane.
• Tissue specificity: Expressed in skeletal muscle, T-cells, megakaryoblastic cells, and platelets.
• KEYWORDS indicate it is a phosphoprotein involved in immunity and inflammatory response, with zinc-finger and kinase domains.
• The protein undergoes alternative splicing and has isopeptide bond and Ubl conjugation modifications.

Experimental Guidance and Technical Tips

• The immunogen design targets phosphorylation at Thr538. To preserve this labile modification, include phosphatase inhibitors in lysis buffers and avoid freeze-thaw cycles of samples.
• For western blotting, use a gentle blocking agent (e.g., 5% BSA) to reduce nonspecific binding; confirm antibody specificity by treating samples with lambda phosphatase before electrophoresis.
• Validation in a relevant cellular context is recommended: in human T-cell lines (e.g., Jurkat) stimulated via anti-CD3/CD28, a band at ~82 kDa should be observed, indicating PRKCQ phosphorylation.
• For ELISA-based detection, a phosphopeptide covering the T538 site can serve as a positive control; cross-reactivity with the unphosphorylated peptide should be evaluated.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio serves as a comprehensive sourcing bridge for IVD manufacturers, offering validated antibody pairs, optimized monoclonal/polyclonal antibodies, and bulk ancillary reagents. This phospho-PRKCQ-T538 polyclonal antibody is part of our portfolio supporting immunological research, particularly in T-cell activation and inflammatory disease biomarker development. We also assist in sourcing rare-target raw materials to accelerate your assay development programs.